Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin and Etoposide. Open. Download Table | Schema for CALGB trial CALGB trial schema from publication: Small Cell Lung Cancer: Have We Made Any Progress Over the . This randomized phase III trial is comparing three different chest radiation therapy regimens to see how well they work in treating patients with limited-stage .

Author: Doukinos Golar
Country: Iran
Language: English (Spanish)
Genre: Politics
Published (Last): 4 June 2009
Pages: 25
PDF File Size: 11.64 Mb
ePub File Size: 4.61 Mb
ISBN: 530-5-25663-932-6
Downloads: 91632
Price: Free* [*Free Regsitration Required]
Uploader: Gutilar

Seidman, MD, and Charles E.

Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer.

A total of 25 patients in the twice-daily radiation therapy group and 32 in the once-daily radiation therapy group did not get concurrent chemoradiation therapy.

An international randomised trial of concurrent chemo-radiotherapy comparing twice-daily and once-daily radiotherapy schedules in patients with limited stage small cell lung cancer and good performance status. It evaluated the optimization of chemoradiotherapy in limited-stage SCLC.


Expert Point of View: Taofeek Kunle Owonikoko, MD. There was one death in the twice-daily group and two in the once-daily group due to radiation pneumonitis.

There was no statistically significant overall survival difference between the groups. Eighty percent of patients had stage III disease.

Comparison of once and twice daily radiotherapy for limited stage small-cell lung cancer.

Adverse events were not significantly different between the two groups as well, with the exception of more neutropenia in patients treated with twice-daily radiation therapy. Clinical Applications of Genomic Studies R. In this trial, survival was higher than previously reported in other trials of this patient population, and radiation toxicities were lower than expected.

By Alice Goodman June 25, Advertisement.

Survival in both arms was higher than previously reported. The study enrolled patients with histologically or cytologically proven SCLC recruited from 73 centers in 7 European countries and Canada between and All analyses were done on an intention-to-treat basis.

No statistically significant differences between the two groups were reported for the rates of progression-free survival or local or metastatic disease progression. It was challenging to accrue patients with this disease.


Patients with any response were offered prophylactic cranial radiation therapy. High-dose radiation therapy to the lungs and esophagus in the once-daily arm did not seem to translate to a significant difference between the arms in terms of esophagitis or pneumonitis. Median overall survival was 30 months vs 25 months, a difference that is not statistically significant. Updated Trial Findings View More. Radiation-related aclgb were lower than expected likely due to the use of modern RT techniques These inconclusive results suggest that either schedule can be used in this setting.

Formal discussant Taofeek Kunle Owonikoko, MDof Winship Cancer Institute of Emory University, Atlanta, said it has been controversial whether to use once-daily or twice-daily radiation therapy in this patient population.